Do adherence rates and glaucomatous visual field progression correlate?

Gemma C M Rossi, Gian Maria Pasinetti, Luigia Scudeller, Rosella Radaelli, Paolo Emilio Bianchi

Research output: Contribution to journalArticlepeer-review


Purpose. To assess the relation between visual field progression and adherence rate in patients with glaucoma using Travatan Dosing Aid® (TDA). Methods. In this 36-month retrospective study, 35 patients with primary open-angle glaucoma on travoprost or travoprost/timolol fixed combination monotherapy were submitted to ophthalmic examination and to visual field (VF) test from 2007 to 2009. Adherence was recorded with TDA. The association between VF progression (from 2007 to the end of the follow-up period) and a number of predictors (adherence rates at 12 months) was tested by means of chi-square test (or Fisher exact test) or Mann-Whitney test as appropriate. Results. The mean (±SD) adherence rates were 71.9%±27.8% after 1 month of follow-up and 76.8%±20.9% at 12 months. A total of 25 (71.4%) patients with stable VF had a median adherence rate (IQR) of 85% (75%-97%); patients who worsened (n=10; 28.6%) recorded a median (IQR) adherence of 21% (9%-45%) (p

Original languageEnglish
Pages (from-to)410-414
Number of pages5
JournalEuropean Journal of Ophthalmology
Issue number4
Publication statusPublished - Jul 2011


  • Adherence
  • Glaucoma
  • Monitoring tools
  • Monotherapy
  • Travatan dosing aid®
  • Visual field progression

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Do adherence rates and glaucomatous visual field progression correlate?'. Together they form a unique fingerprint.

Cite this